Osmotica Pharmaceuticals plc (OSMT) financial statements (2021 and earlier)

Company profile

Business Address 400 CROSSING BOULEVARD
BRIDGEWATER, NJ 08807
State of Incorp.
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
ASSETS
Current Assets
Receivables264456
Inventory, net of allowances, customer advances and progress billings182124
Inventory182124
Other undisclosed current assets12910792
Total current assets:173173172
Noncurrent Assets
Finance lease, right-of-use asset0 
Operating lease, right-of-use asset35
Property, plant and equipment23031
Intangible assets, net (including goodwill)167255591
Goodwill101101101
Intangible assets, net (excluding goodwill)66154490
Other noncurrent assets011
Other undisclosed noncurrent assets26  
Total noncurrent assets:198291623
TOTAL ASSETS:371463796
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities5474113
Accounts payable7825
Accrued liabilities486587
Taxes payable0 0
Debt022
Other undisclosed current liabilities1  
Total current liabilities:5676114
Noncurrent Liabilities
Long-term debt and lease obligation221271267
Long-term debt, excluding current maturities220268267
Finance lease, liability00
Capital lease obligations0
Operating lease, liability13
Liabilities, other than long-term debt0228
Accounts payable and accrued liabilities  2
Deferred tax liabilities, net26
Deferred income tax liabilities02
Total noncurrent liabilities:221273295
Total liabilities:277349409
Stockholders' equity
Stockholders' equity attributable to parent94115386
Common stock111
Additional paid in capital548489490
Accumulated other comprehensive loss(2)(2)(2)
Accumulated deficit(453)(373)(102)
Total stockholders' equity:94115386
TOTAL LIABILITIES AND EQUITY:371463796

Income statement (P&L) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
Revenues178240264
Cost of revenue
(Cost of Goods and Services Sold)
(74)(112)(135)
Gross profit:103128129
Operating expenses(174)(409)(227)
Operating loss:(70)(281)(99)
Nonoperating income (expense)11(20)
Interest and debt expense(14)(18)(1)
Loss from continuing operations before equity method investments, income taxes:(84)(298)(120)
Other undisclosed income from continuing operations before income taxes  1
Loss from continuing operations before income taxes:(84)(298)(119)
Income tax benefit5279
Net loss available to common stockholders, diluted:(80)(271)(109)

Comprehensive Income ($ in millions)

12/31/2020
12/31/2019
12/31/2018
Net loss:(80)(271)(109)
Comprehensive loss:(80)(271)(109)
Other undisclosed comprehensive loss, net of tax, attributable to parent (0)(1)
Comprehensive loss, net of tax, attributable to parent:(80)(271)(111)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: